Autor(es): Torres-Obreque, Karin M. ; Meneguetti, Giovanna P. ; Muso-Cachumba, Jorge J. ; Feitosa, Valker A. ; Santos, João H. P. M. ; Ventura, Sónia P. M. ; Rangel-Yagui, Carlota O.
Data: 2022
Identificador Persistente: http://hdl.handle.net/10773/35522
Origem: RIA - Repositório Institucional da Universidade de Aveiro
Assunto(s): Biobetter; Biodegradable polymer; Fusion protein; Glycoengineering; PEGylation; Protein engineering
Biological drugs or biopharmaceuticals off patent open a large market for biosimilars and biobetters, follow-on biologics. Biobetters, in particular, are new drugs designed from existing ones with improved properties such as higher selectivity, stability, half-life and/or lower toxicity/immunogenicity. Glycosylation is one of the most used strategies to improve biological drugs, nonetheless bioconjugation is an additional alternative and refers to the covalent attachment of polymers to biological drugs. Extensive research on novel polymers is underway, nonetheless PEGylation is still the best alternative with the longest clinical track record. Innovative trends based on genetic engineering techniques such as fusion proteins and PASylation are also promising. In this review, all these alternatives wereexplored as well as current market trends, legislation and future perspectives.
